Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Leukemia

About this trial
This is an interventional treatment trial for Leukemia focused on measuring adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), secondary acute myeloid leukemia, untreated adult acute myeloid leukemia
Eligibility Criteria
DISEASE CHARACTERISTICS:
Inclusion criteria:
Newly diagnosed acute myeloid leukemia (AML)
- Morphologic proof (bone marrow aspirate smears or touch prep of marrow biopsy) of disease
- FAB M0, M1, M2, M4, M5a, M5b, M6a, M6b, and M7 disease
Previously untreated with radiotherapy or chemotherapy
- Patients with treatment-related leukemia are eligible even if they have received prior chemotherapy and radiotherapy
- Patients with prior myelodysplastic syndrome are eligible
- Extramedullary leukemia allowed
- AML with lymphoid markers allowed
Exclusion criteria:
- Blastic transformation of chronic myelogenous leukemia
- Biphenotypic leukemia
- FAB M3 disease (acute promyelocytic leukemia)
PATIENT CHARACTERISTICS:
- Life expectancy ≥ 6 weeks
- Total bilirubin < 1.5 g/dL
- AST and ALT < 5 times upper limit of normal (ULN)
- Creatinine < 1.5 mg/dL OR creatinine clearance > 70 mL/min
- Ejection fraction ≥ 50% by MUGA unless decreased ejection fraction is secondary to leukemia infiltration
- HIV antibody-negative
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- See Disease Characteristics
- Prior hydroxyurea or corticosteroids allowed
- At least 48 hours since prior and no concurrent itraconazole or fluconazole
Exclusion criteria:
- More than 300 mg/m² of prior daunorubicin or equivalent dose of anthracycline
Sites / Locations
- Banner Good Samaritan Medical Center
- City of Hope Comprehensive Cancer Center
Arms of the Study
Arm 1
Experimental
Treatment (idarubicin, cytarabine)
Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.